van Dijk B A, Drenthe-Schonk A M, Bloo A, Kunst V A, Janssen J T, de Witte T J
Blood Transfusion Service, St. Radboud University Hospital, Nijmegen, The Netherlands.
Transplantation. 1987 Nov;44(5):650-4. doi: 10.1097/00007890-198711000-00011.
Blood samples from 31 of 50 consecutive patients receiving bone marrow from an HLA-identical and mixed lymphocyte culture-nonreactive sibling were investigated for the presence of donor and autologous erythrocytes. Simple serological techniques using antigenic differences between donor and recipient and a blood transfusion policy taking these differences into account made this study possible. A total of 71% of the patients had donor erythrocytes demonstrable 4 weeks after bone marrow transplantation; almost all patients did so after 2 months. Disappearance or absence of donor red cells indicated poor patient prognosis. Persistence or reappearance of autologous erythrocytes in small percentages (0.05-10%) occurred without relapse of leukemia. Reappearance in high percentage (50-100%) indicated relapse.
对50例连续接受来自人类白细胞抗原（HLA）相同且混合淋巴细胞培养无反应性同胞的骨髓移植患者中的31例进行了血样检测，以确定是否存在供体和自体红细胞。利用供体和受体之间的抗原差异的简单血清学技术以及考虑到这些差异的输血策略使得这项研究成为可能。共有71%的患者在骨髓移植后4周可检测到供体红细胞；几乎所有患者在2个月后均可检测到。供体红细胞消失或不存在表明患者预后不良。少量自体红细胞（0.05 - 10%）持续存在或再次出现，白血病未复发。高比例（50 - 100%）再次出现则表明复发。
